Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.70 +0.4%	$6.55	$2.33 ▼ $39.00	$2.06M	0.88	66,661 shs	71,785 shs
CLDI Calidi Biotherapeutics	$1.74 +2.4%	$5.37	$1.61 ▼ $46.68	$5.27M	1.15	649,763 shs	533,723 shs
CUR Neuralstem	$0.75 +3.9%	$1.06	$1.10 ▼ $13.78	$1.58M	1.81	236,278 shs	210,736 shs
NKGN NKGen Biotech	$0.13	$0.22	$0.10 ▼ $0.96	$5.96M	1.19	1.61 million shs	3,139 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	0.00%	+1.89%	-67.86%	-70.46%	-92.69%
CLDI Calidi Biotherapeutics	0.00%	-67.17%	-80.14%	-64.67%	-87.11%
CUR Neuralstem	0.00%	-5.87%	-32.07%	-6.57%	-78.02%
NKGN NKGen Biotech	0.00%	-5.36%	-30.26%	-54.28%	-84.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.1599 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.0	0.0
CLDI Calidi Biotherapeutics	0.737 of 5 stars	0.0	4.0	0.0	0.0	2.3	0.0	0.6
CUR Neuralstem	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,085.19% Upside
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
CUR Neuralstem	0.00	N/A	N/A	N/A
NKGN NKGen Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$121K	17.05	N/A	N/A	$0.20 per share	13.50
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
CUR Neuralstem	$260K	6.09	N/A	N/A	$6.64 per share	0.11
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	($2.68) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
CUR Neuralstem	-$4.93M	N/A	0.00	∞	N/A	-39,417.64%	-170.51%	-110.16%	N/A
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CUR Neuralstem	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
CUR Neuralstem	N/A	2.53	2.53
NKGN NKGen Biotech	N/A	0.02	0.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
CLDI Calidi Biotherapeutics	12.53%
CUR Neuralstem	38.30%
NKGN NKGen Biotech	76.17%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
CLDI Calidi Biotherapeutics	6.70%
CUR Neuralstem	5.38%
NKGN NKGen Biotech	10.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
CUR Neuralstem	6	2.10 million	N/A	Not Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable

CUR, NKGN, CLDI, and AIM Headlines

Recent News About These Companies

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit

August 6, 2025 | globenewswire.com

NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025

July 29, 2025 | finance.yahoo.com

NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025

July 28, 2025 | globenewswire.com

NKGen Biotech to Present at the Alzheimer's Association International Conference 2025

July 22, 2025 | globenewswire.com

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

July 21, 2025 | finance.yahoo.com

NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan

July 17, 2025 | globenewswire.com

NKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards

July 17, 2025 | finanznachrichten.de

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards

July 16, 2025 | globenewswire.com

NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s ...

July 12, 2025 | morningstar.comM

NKGen Biotech, Inc.: NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

July 11, 2025 | finanznachrichten.de

NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

July 10, 2025 | globenewswire.com

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida

June 23, 2025 | globenewswire.com

Nkgen biotech sees $2.5 million stock purchase by major shareholder

June 4, 2025 | investing.com

NKGen Biotech Enters Stock Purchase Agreement

May 20, 2025 | tipranks.com

NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer’s readout

May 8, 2025 | fiercebiotech.comF

NKGen Biotech Chairman & CEO Paul Y. Song, M.D.

May 8, 2025 | globenewswire.com

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

May 7, 2025 | finance.yahoo.com

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

April 14, 2025 | globenewswire.com

NKGen Biotech presents data from Phase 1/2a trial of troculeucel

April 9, 2025 | markets.businessinsider.com

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

April 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Top Headlines

View All

CUR, NKGN, CLDI, and AIM Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.70 +0.01 (+0.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.71 +0.01 (+0.37%)

As of 04:59 AM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Calidi Biotherapeutics NYSE:CLDI

$1.74 +0.04 (+2.35%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.01 (+0.86%)

As of 05:03 AM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

NKGen Biotech NYSE:NKGN

$0.13 0.00 (0.00%)

As of 08/22/2025 03:35 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time